NanoViricides Inc. (NNVC)

[Puffer]

that information is way out of date, is NOT in the latest 10K, and does NOT include mention of the very broad patent issued (PCT/US06/01820
(SOLUBILIZATION AND TARGETED DELIVERY OF DRUGS WITH SELF-ASSEMBLING AMPHIPHILIC POLYMERS) in May of last year.

We have previously announced certain important issuances of patents on the TheraCour® technology underlying our nanoviricides® drugs. Most importantly, a fundamental patent on the polymeric micelles composition, structure and uses was issued in the USA with substantially broad claims. This validates the novelty of our approach as well as our leadership position in the nanomedicines based on polymeric micelle technologies. All of the patent applications have been filed internationally. To date more than 20 patent grants have occurred and additional grants continue as the applications progress through review.

substantially broad claims.... doesn't sound so inferior does it?

Here is what was completely twisted by the author of that article --

Of the patents and technologies licensed, the Company believes that the Company will not be using the intellectual property, compositions of matter, or other aspects described and secured under the US Patent No. US 6,521,736. The Company believes that this patent describes an inferior technology compared to the technology in the later patent filings of Dr. Diwan. This patent, the Company believes, discloses prototype materials that served to establish the proof of principles developed by Dr. Anil Diwan, the Company’s President and co- founder, whether such materials were possible to create and whether such materials would indeed be capable of encapsulation of pharmaceutically relevant compounds. The Company believes that the new and novel compositions disclosed in the new patent applications, No. PCT/US06/01820, and No. PCT/US2007/001607, and additional proprietary intellectual property provide the necessary features that enable the development of nanoviricides. The Company believes that no other published literature materials or existing patents are capable of providing all of the necessary features for this development, to the best of our knowledge. However, the Company has no knowledge of the extensive active internal developments at a number of companies in the targeted therapeutics area.

No partnerships with Big Pharma yet because they are extremely risk averse and usually wait until proof of efficacy in humans. A successful Phase I/IIa and they will come flocking.

You guys seem to want nothing to do with anything that may be seen as adverse and attack it.

No, its just that all the unsubstantiated false claims gets tiring. Bring a valid point and we will be all over it. Too many times, it appears, the correction of outright falsehoods gets taken as not wanting to hear anything negative about the company. Complete nonsense.